Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
|Niemann–Pick disease, type C|
|Classification and external resources|
|ICD-10||E752 (ILDS E75.230)|
Niemann–Pick type C is a lysosomal storage disease associated with mutations in NPC1 and NPC2 genes. Niemann–Pick type C strikes an estimated 1:150,000 people. Approximately 50% of cases present before 10 years of age, but manifestations may first be recognized as late as the sixth decade.
Niemann–Pick type C is biochemically, genetically and clinically distinct from Niemann–Pick Types A or and B. In Types A & B, there is complete or partial deficiency of an enzyme called acid sphingomyelinase. In Niemann–Pick type C, the protein product of the major mutated gene NPC1 is not an enzyme but appears to function as a transporter in the endosomal-lysosomal system, which moves large water-insoluble molecules through the cell. The protein coded by the NPC2 gene more closely resembles an enzyme structurally but seems to act in cooperation with the NPC1 protein in transporting molecules in the cell. The disruption of this transport system results in the accumulation of cholesterol and glycolipids in lysosomes.
Cholesterol and glycolipids have varied roles in the cell. Cholesterol is a major component of cell plasma membranes, which define the cell as a whole and its organelles. It is also the basic building block of steroid hormones, including neurosteroids. In Niemann–Pick type C, large amounts of free or unesterfied cholesterol accumulates in lysosomes, and leads to relative deficiency of this molecule in multiple membranes and for steroid synthesis. The accumulation of glycosphingolipids in the nervous system has been linked to structural changes, namely ectopic dendritogenesis and meganeurite formation, and has been targeted therapeutically.
Several theories have attempted to link the accumulation of cholesterol and glycolipids in the lysosomes with the malfunction of the NPC-1 protein.
- Another theory suggests that the blockage of retrograde cholesterol breakdown in the late endosome is due to decreased membrane elasticity and thus the return vesicles of cholesterol to the trans Golgi Network cannot bud and form.
- Iouannou, et al. have described similarities between the NPC1 protein and members of the resistance-nodulation-division (RND) family of prokaryotic permeases, suggesting a pumping function for NPC1.
Genetics and classificationEdit
Approximately 95% of Niemann–Pick type C cases are caused by genetic mutations in the NPC1 gene, referred to as type C1; 5% are caused by mutations in the NPC2 gene, referred to as type C2. The clinical manifestations of types Niemann–Pick types C1 and C2 are similar because the respective genes are both involved in egress of lipids, particularly cholesterol, from late endosomes or lysosomes. The NPC1 gene is located on chromosome 18 (18q11-q12) and was described by researchers at the National Institutes of Health in July 1997.
- The NPC1 gene encodes a protein that is located in membranes inside the cell and is involved in the movement of cholesterol and lipids within cells. A deficiency of this protein leads to the abnormal build up of lipids and cholesterol within cell membranes.
- The NPC2 gene encodes a protein that binds and transports cholesterol. It has been shown to closely interact with NPC1.
"Type D" variantEdit
Genelogical research indicates that Joseph Muise (c. 1679 – 1729) and Marie Amirault (1684 – c. 1735) are common ancestors to all people with Type D. This couple is the most likely origin for the type D variant.
Niemann–Pick type C has a wide clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen/liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth. In some cases, however, enlargement of the spleen and/or liver does not occur for months or years – or not at all. Enlargement of the spleen and/or liver frequently becomes less apparent with time, in contrast to the progression of other lysosomal storage diseases such as Niemann–Pick disease, Types A and B or Gaucher disease. Organ enlargement does not usually cause major complications.
Progressive neurological disease is the hallmark of Niemann–Pick type C disease, and is responsible for disability and premature death in all cases beyond early childhood. Classically, children with NPC may initially present with delays in reaching normal developmental milestones skills before manifesting cognitive decline (dementia).
Neurological signs and symptoms include cerebellar ataxia (unsteady walking with uncoordinated limb movements), dysarthria (slurred speech), dysphagia (difficulty in swallowing), tremor, epilepsy (both partial and generalized), vertical supranuclear palsy (upgaze palsy, downgaze palsy, saccadic palsy or paralysis), sleep inversion, gelastic cataplexy (sudden loss of muscle tone or drop attacks), dystonia (abnormal movements or postures caused by contraction of agonist and antagonist muscles across joints), most commonly begins with in turning of one foot when walking (action dystonia) and may spread to become generalized, spasticity (velocity dependent increase in muscle tone), hypotonia, ptosis (drooping of the upper eyelid), microcephaly (abnormally small head), psychosis, progressive dementia, progressive hearing loss, bipolar disorder, major and psychotic depression that can include hallucinations, delusions, mutism, or stupor.
In the terminal stages of Niemann–Pick type C disease, the patient is bedridden, with complete ophthalmoplegia, loss of volitional movement and has severe dementia.
Niemann–Pick type C is diagnosed by assaying cultured fibroblasts for cholesterol esterfication and staining for unesterified cholesterol with filipin. The fibroblasts are grown from a small skin biopsy taken from a patient with suspected NPC. The diagnosis can be confirmed by identifying mutations in the NPC1 or NPC2 genes in 80–90% of cases. This specialized testing is available at Thomas Jefferson University Lysosomal Disease Testing Lab and the Mayo Clinic.
There is no known cure for Niemann–Pick type C, nor is there any FDA-standard approved disease modifying treatment. Supportive care is essential and substantially improves the quality of life of people affected by NPC. The therapeutic team may include specialists in neurology, pulmonology, gastroenterology, psychiatrist, orthopedics, nutrition, physical therapy and occupational therapy. Standard medications used to treat symptoms can be used in NPC patients. As patients develop difficulty with swallowing, food may need to be softened or thickened, and eventually, parents will need to consider placement of a gastrostomy tube (g-tube, feeding tube).
An observational study is underway at the National Institutes of Health to better characterize the natural history of NPC and to attempt to identify markers of disease progression.
In April 2009, Hydroxypropyl-beta-cyclodextrin (HPbCD) was approved under compassionate use by the U.S. Food and Drug Administration (FDA) to treat Addison and Cassidy Hempel, identical twin girls suffering from Niemann–Pick type C disease. Medi-ports, similar to ports used to administer chemotherapy drugs, were surgically placed into the twins' chest walls and allow doctors to directly infuse HPbCD into their bloodstreams. Treatment with cyclodextrin has been shown to delay clinical disease onset, reduced intraneuronal storage and secondary markers of neurodegeneration, and significantly increased lifespan in both the Niemann–Pick type C mice and feline models. (This is the second time in the United States that cyclodextrin alone has been administered in an attempt treat a fatal pediatric disease. Over 20 years ago, HPbCD was used in a medical case involving a boy suffering from severe hypervitaminosis A.)
On May 17, 2010, the FDA granted Hydroxypropyl-beta-cyclodextrin orphan drug status and designated the compound as a potential treatment for Niemann–Pick type C disease. On July 14, 2010, Dr. Caroline Hastings of Children's Hospital Oakland filed additional applications with the FDA requesting approval to deliver HPbCD directly into the central nervous system of the twins in an attempt to help HPbCD cross the blood–brain barrier. The request was approved by the FDA on September 23, 2010, and bi-monthly intrathecal injections of HPbCD into the spine were administered starting in October 2010. Additional filings have been made to the FDA by Children's Hospital Research Center Oakland requesting approval to surgically implant Medtronic SynchroMed pumps into the twins to deliver continuous doses of HPbCD into their brains.
On December 25, 2010, the FDA granted approval for HPbCD to be delivered via IV to an additional patient, Peyton Hadley, aged 13 under an IND through Rogue Regional Medical Center in Medford, Oregon. Soon after in March 2011, approval was sought for similar treatment of his sibling, Kayla, age 11, and infusions of HPbCD began shortly after. Both have since began Intrathecal treatments beginning in January 2012. (www.hadleyhope.com)
On December 31, 2011 the FDA granted approval for IV HpBCD infusions for a fifth child in the United States, Chase DiGiovanni. He infuses under a compassionate use protocol and was 29 months old at the time of his first infusion in January 2012. The study was halted by the FDA in Spring of 2012 for further review and allowed to resume in October 2012 at a secondary site. Due to unprecedented collaboration between the parents of afflicted children HpBCD INDs have been able to be obtained outside of a formal trial. (www.chasethecure.net)
In April 2011, the National Institutes of Health (NIH), in collaboration with the Therapeutics for Rare and Neglected Diseases Program (TRND), announced they are developing a clinical trial utilizing cyclodextrin for Niemann–Pick type C patients. The clinical trial is in the planning phase is not yet approved by the FDA.
Other treatments under investigationEdit
One drug that has been tried is Miglustat. Miglustat is a glucosylceramide synthase inhibitor, which inhibits the synthesis of glycosphingolipids in cells. It has been shown to delay the onset of disease in the NPC mouse, and published data from a multi-center clinical trial of Miglustat in the United States and England and from case reports suggests that it may ameliorate the course of human NPC.
Several other treatment strategies are under investigation in cell culture and animal models of NPC. These include, cholesterol mobilization, neurosteroid (a special type of hormone that affects brain and other nerve cells) replacement using allopregnanolone, rab overexpression to bypass the trafficking block (Pagano lab) and Curcumin as an anti-inflammatory and calcium modulatory agent. The pregnane X receptor has been identified as a potential target.
The lifespan of patients with NPC is usually related to the age of onset. Children with antenatal or infantile onset usually succumb in the first few months or years of life, whereas adolescent and adult onset forms of Niemann–Pick type C have a more insidious onset and slower progression, and affected individuals may survive to the seventh decade. Adult cases of NPC are being recognized with increasing frequency. It is suspected that many patients affected by NPC are undiagnosed, owing to lack of awareness of the disease and the absence of readily available screening or diagnostic tests. For the same reasons the diagnosis is often delayed by many years.
Loss of myelin in the Central Nervous System is considered to be a main pathogenic factor. Research uses animal models carrying the underlying mutation for Niemann-Pick disease, e.g. a mutation in the NPC1 gene Niemann-Pick type C disease. In this model the expression of Myelin gene Regulatory Factor (MRF) has been shown to be significantly decreased. MRF is a transcription factor of critical importance in the development and maintenance of myelin sheaths. A perturbation of oligodendrocyte maturation and the myelination process might therefore be an underlying mechanism of the neurological deficits.
- Ara Parseghian Medical Research Foundation is a major funder of Niemann-Pick Type C Disease research
- National Niemann–Pick Disease Foundation; A family support, research and patient advocacy group for families with loved ones diagnosed with Niemann–Pick Disease.
- GeneReviews/NCBI/NIH/UW entry on Niemann–Pick Disease type C
- OMIM entries on Niemann–Pick type C
- National Institutes of Health Clinical Center Study On Niemann–Pick type C
- Marc C. Patterson, MD, child neurologist, Mayo Clinic
- Coriell Institute: Biobank that stores Niemann–Pick type C cells for research
- Addi and Cassi Hempel: Identical twins living with Niemann–Pick type C disease
- Testing labs for Niemann–Pick type C
- Clinical Description of Niemann–Pick type C
- Dana's Angels Research Trust...aiming to cure NPC
- Hide & Seek Foundation for Lysosomal Disease Research
- Global Genes Project, Rare Disease Support Organization
- Detailed information about Niemann–Pick type C for patients and Healthcare Professionals incl. Glossary
- Portuguese description of Niemann–Pick type C, support and resources
- ↑ Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CC (June 2005). Niemann–Pick type C disease and intracellular cholesterol trafficking. The Journal of Biological Chemistry 280 (22): 20917–20.
- ↑ Neufeld EB, Wastney M, Patel S, et al. (1999). The Niemann–Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J. Biol. Chem. 274 (14): 9627–9635.
- ↑ Davies JP, Chen FW, Ioannou YA (2000). Transmembrane molecular pump activity of Niemann–Pick C1 protein. Science 290 (5500): 2295–2298.
- ↑ 4.0 4.1 Lloyd-Evans E, Morgan AJ, He X, et al. (October 2008). Niemann–Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nature Medicine 14 (11): 1247–55.
- ↑ 5.0 5.1 Mellon SH, Gong W, Schonemann MD (March 2008). Endogenous and synthetic neurosteroids in treatment of Niemann–Pick Type C disease. Brain Research Reviews 57 (2): 410–20.
- ↑ genome.gov. URL accessed on 2008-10-27. [dead link]
- ↑ Zhang JR, Coleman T, Langmade SJ, et al. (June 2008). Niemann–Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. The Journal of Clinical Investigation 118 (6): 2281–90.
- ↑ Bjurulf B, Spetalen S, Erichsen A, Vanier MT, Strøm EH, Strømme P (August 2008). Niemann–Pick disease type C2 presenting as fatal pulmonary alveolar lipoproteinosis: morphological findings in lung and nervous tissue. Medical science monitor : international medical journal of experimental and clinical research 14 (8): CS71–5.
- ↑ Liou HL, Dixit SS, Xu S, Tint GS, Stock AM, Lobel P (December 2006). NPC2, the protein deficient in Niemann–Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols. The Journal of Biological Chemistry 281 (48): 36710–23.
- ↑ Infante RE, Wang ML, Radhakrishnan A, Kwon HJ, Brown MS, Goldstein JL (October 2008). NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proceedings of the National Academy of Sciences of the United States of America 105 (40): 15287–92.
- ↑ Subramanian K, Balch WE (October 2008). NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proceedings of the National Academy of Sciences of the United States of America 105 (40): 15223–4.
- ↑ Winsor EJ, Welch JP (September 1978). Genetic and demographic aspects of Nova Scotia Niemann–Pick disease (type D). American Journal of Human Genetics 30 (5): 530–8.
- ↑ Rimkunas VM, Graham MJ, Crooke RM, Liscum L (September 2008). TNF-alpha plays a role in hepatocyte apoptosis in Niemann–Pick type C liver disease. Journal of lipid research 50 (2): 327–33.
- ↑ Thomas Jefferson University – Lysosomal Diseases Testing Laboratory. URL accessed on 2008-10-27. Template:Archive link
- ↑ Niemann–Pick Diagnosis. URL accessed on 2008-10-27.
- ↑ Pacheco CD, Lieberman AP (2008). The pathogenesis of Niemann–Pick type C disease: a role for autophagy?. Expert Reviews in Molecular Medicine 10: e26.
- ↑ Niemann–Pick Disease Type C -- GeneReviews -- NCBI Bookshelf. URL accessed on 2008-10-27.
- ↑ Davidson CD, Ali NF, Micsenyi MC, et al. (2009). Chronic cyclodextrin treatment of murine Niemann–Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 4 (9): e6951.
- ↑ Ward S, O'Donnell P, Fernandez S, Vite CH (July 2010). 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann–Pick type C disease. Pediatr. Res. 68 (1): 52–6.
- ↑ Carpenter TO, Pettifor JM, Russell RM, et al. (October 1987). Severe hypervitaminosis A in siblings: evidence of variable tolerance to retinol intake. J. Pediatr. 111 (4): 507–12.
- ↑ Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (September 2007). Miglustat for treatment of Niemann–Pick C disease: a randomised controlled study. Lancet neurology 6 (9): 765–72.
- ↑ Santos ML, Raskin S, Telles DS, et al. (October 2008). Treatment of a child diagnosed with Niemann–Pick disease type C with miglustat: A case report in Brazil. Journal of Inherited Metabolic Disease.
- ↑ Ahmad I, Lope-Piedrafita S, Bi X, et al. (December 2005). Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann–Pick C mice. Journal of neuroscience research 82 (6): 811–21.
- ↑ Langmade SJ, Gale SE, Frolov A, et al. (September 2006). Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann–Pick C disease. Proceedings of the National Academy of Sciences of the United States of America 103 (37): 13807–12.
- ↑ Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP (2007). Neural stem cell implantation extends life in Niemann–Pick C1 mice. Journal of applied genetics 48 (3): 269–72.
- ↑ eMedicine – Niemann–Pick Disease : Article by Robert A Schwartz. URL accessed on 2008-10-27.
- ↑ Niemann–Pick Disease. URL accessed on 2008-10-27.
- ↑ 28.0 28.1 Yan, X., Lukas, J.; Witt, M.; Wree, A.; Hubner, R.; Frech, M.; Kohling, R.; Rolfs, A.; Luo, J. (2011-09-23). Decreased expression of myelin gene regulatory factor in Niemann-Pick type C 1 mouse. Metab Brain Dis 26 (4): 299–306.
- ↑ Koenning, Matthias, Jackson, Stacey Hay, Curtis M. Faux, Clare Kilpatrick, Trevor J. Willingham, Melanie Emery, Ben (September 5, 2012). Myelin Gene Regulatory Factor Is Required for Maintenance of Myelin and Mature Oligodendrocyte Identity in the Adult CNS. The Journal of Neuroscience 32 (36): 12528–12542.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|